{
    "url_original": "https://www.wsj.com/articles/fda-authorizes-use-of-new-eli-lilly-covid-19-antibody-treatment-11644618832?mod=politics_lead_pos12",
    "url": "fda-authorizes-use-of-new-eli-lilly-covid-19-antibody-treatment-11644618832",
    "title": "FDA Authorizes Use of New Eli Lilly Covid-19 Antibody Treatment",
    "sub_head": "The drug retains effectiveness against the Omicron variant",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-484823?width=860&height=573",
    "image_1": "im-484823.jpg",
    "time": "2022-02-11 17:33:00",
    "body": "U.S. drug regulators authorized the use of a new Covid-19 antibody drug from  Eli Lilly  & Co. that retains effectiveness against the Omicron variant of the virus, filling a void after authorities stopped distributing some older antibody drugs that lost effectiveness against the strain.<br />The Food and Drug Administration on Friday cleared the drug, bebtelovimab, for the treatment of mild to moderate Covid-19 in nonhospitalized individuals 12 and older who are at high risk of getting severely sick. The drug is intended for people who can’t get access to alternative Covid-19 treatments, or for whom those treatments aren’t appropriate."
}